Introduction:
The biologics market in Denmark is experiencing significant growth in 2026, following global trends of increasing demand for biopharmaceuticals. Denmark is known for its strong biotech industry, with a focus on research and development in the field of biologics. With a production volume of over 1.5 billion USD and a market size expected to reach 3 billion USD by the end of the year, Denmark is a key player in the biologics market.
Top 10 Biologics Manufacturers in Denmark 2026:
1. Novo Nordisk A/S
With a production volume of 800 million USD and a market share of 30%, Novo Nordisk A/S is the leading biologics manufacturer in Denmark. Known for its innovative insulin products, the company continues to expand its portfolio in the biopharmaceutical sector.
2. Genmab A/S
Genmab A/S holds the second position with a production volume of 500 million USD and a market share of 20%. The company specializes in developing antibody therapeutics for the treatment of cancer and other diseases.
3. Lundbeck A/S
Lundbeck A/S is a key player in the biologics market in Denmark with a production volume of 300 million USD. The company focuses on developing biopharmaceuticals for the treatment of neurological and psychiatric disorders.
4. Bavarian Nordic A/S
Bavarian Nordic A/S has a production volume of 200 million USD and a market share of 10%. The company is known for its vaccines and immunotherapies for infectious diseases and cancer.
5. ALK-Abelló A/S
With a production volume of 150 million USD, ALK-Abelló A/S is a prominent biologics manufacturer in Denmark. The company specializes in allergy immunotherapy products.
6. Zealand Pharma A/S
Zealand Pharma A/S has a production volume of 100 million USD and focuses on developing peptide-based therapeutics for metabolic and gastrointestinal diseases.
7. Ascendis Pharma A/S
Ascendis Pharma A/S is a rapidly growing biologics manufacturer in Denmark with a production volume of 80 million USD. The company is known for its innovative approaches to drug delivery and development.
8. Symphogen A/S
Symphogen A/S has a production volume of 60 million USD and specializes in developing antibody therapeutics for the treatment of cancer and autoimmune diseases.
9. Orphazyme A/S
Orphazyme A/S is a biopharmaceutical company with a production volume of 40 million USD. The company focuses on developing treatments for rare genetic disorders.
10. 3B Pharmaceuticals GmbH
3B Pharmaceuticals GmbH is a biologics manufacturer with a production volume of 30 million USD. The company focuses on developing peptide-based therapeutics for cancer and other diseases.
Insights:
The biologics market in Denmark is expected to continue its growth trajectory in the coming years, driven by increasing investment in research and development. With an estimated market size of 3.5 billion USD by 2030, Denmark is poised to become a key player in the global biopharmaceutical industry. The country’s strong regulatory framework and skilled workforce make it an attractive destination for biologics manufacturers looking to expand their presence in Europe. As the demand for innovative biopharmaceuticals continues to rise, Denmark’s biotech industry is set to thrive in the years to come.
Related Analysis: View Previous Industry Report
